From: The tumor ecosystem in head and neck squamous cell carcinoma and advances in ecotherapy
Target | Drugs | Phase | Patient enrolled | Trial ID |
---|---|---|---|---|
Inhibit tumor angiogenesis | ||||
EGFR | BIBW 2992 | Phase 2 | Metastatic (stage IVc) or recurrent HNC | NCT00514943 |
VEGFR-1, -2 and -3 | Axitinib | Phase 2 | Unresectable R/M HNSCC | NCT02762513 |
EGFR, HER2 and HER4 | Poziotinib (HM781-36B) | Phase 2 | R/M HNSCC after failure of or unfit for platinum-containing therapy | NCT02216916 |
- | Endostatins | Phase 3 | R/M HNSCC not suitable for operation or radiotherapy | NCT02630264 |
EGFR | Panitumumab | Phase 2 | R/M HNC incurable by surgery or radiotherapy | NCT00446446 |
EGFR | Zalutumumab | Phase 2 | HNSCC incurable with standard therapy | NCT00542308 |
EGFR | Lapatinib | Phase 2 | R/M HNC | NCT00114283 |
VEGFR | Cediranib | Phase 2 | Recurrent or newly diagnosed metastatic HNC | NCT00458978 |
Disrupt metabolic homeostasis | ||||
 | Metformin | Early Phase 1 | Stage II-IVB HNSCC | NCT02402348 |
Anti-tumor immunity | ||||
PD-1 | Cemiplimab-Rwlc | Phase 2 | HNSCC after completion of chemotherapy and radiation treatment | NCT04831450 |
PD-1/PD-L1 | Durvalumab | Phase 1 | Non-metastatic, suitable for surgical resection, and stage II-IVB oral cavity, stage III-IVB larynx and hypopharynx, or stage III-IVB HPV/p16 negative intermediate-high risk oropharynx HNC | NCT03635164 |
PD-1 | Pembrolizumab | Phase 2 | R/M HNSCC | NCT03813836 |
PD-L1 | Atezolizumab | Phase 2 | Resectable HNSCC | NCT04939480 |
PD-L1/ TGF-β | Bintrafusp alfa | Phase 2 | Operable and untreated HNSCC | NCT04428047 |
PD-L1/ CD47 | PF-07257876 | Phase 1 | Advanced or metastatic HNSCC, non-small cell lung cancer, and ovarian cancer | NCT04881045 |
CD47 | Evorpacept in combination with pembrolizumab, cisplatin/carboplatin and 5-FU | Phase 2 | Advanced HNSCC | NCT04675333 |
CD47 | Evorpacept in combination with pembrolizumab | Phase 2 | Advanced HNSCC | NCT04675294 |
IL-1β, IL-2, IL-6, IL-8, GM-CSF, INFγ, TNF-α | IRX-2 | Phase 2 | Untreated and resectable HNSCC | NCT00210470 |